Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 13/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.32 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17882326 | 0.92 | PGR (0.41) | PGR | |
| SCHEMBL17882429 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL14702096 | 0.80 | PTPRC (0.38) | PGRPDK2PDK4 | |
| SCHEMBL29456914 | 0.77 | ALDH1A1 (0.40) | PGRPDK2 | |
| SCHEMBL22271342 | 0.77 | ALDH1A1 (0.40) | PGRPDK2 | |
| SCHEMBL24279353 | 0.77 | CYP2A6 (0.41) | PGRPDK2 | |
| SCHEMBL10045895 | 0.75 | TDP1 (0.43) | PGRPDK2MAOBGRIA1CACNG8 | |
| SCHEMBL18463604 | 0.75 | IDO1 (0.39) | PGRPDK2MAOAMAOB | |
| SCHEMBL24751562 | 0.75 | PDK2 (0.35) | PGRPDK2 | |
| SCHEMBL25540973 | 0.75 | PGR (0.47) | PGRPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237387-B1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-3237387-B1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| US-10636979-B2 | Heterocyclic compounds with dibenzazapine structures | MERCK PATENT GMBH (DE) | 2020-04-28 | — | — | US | disclosed |
| US-10636979-B2 | Heterocyclic compounds with dibenzazapine structures | MERCK PATENT GMBH (DE) | 2020-04-28 | — | — | US | disclosed |
| US-20180331301-A1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRUCTURES | MERCK PATENT GMBH (DE) | 2018-11-15 | — | — | US | disclosed |
| EP-3237387-A1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES | Merck Patent GmbH (DE) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102039-A1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016102039-A1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRCTURES | MERCK PATENT GMBH (DE) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10636979-B2 | Heterocyclic compounds with dibenzazapine structures | DDT, MAOA, MAOB | PGR 1900/4885PDK2 942/4885PDK4 1337/4885 |
| US-20180331301-A1 | HETEROCYCLIC COMPOUNDS WITH DIBENZAZAPINE STRUCTURES | DDT, MAOA, MAOB | PGR 1900/4885PDK2 942/4885PDK4 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.